Treatment for Parkinson Disease

Phase-Based Estimates
1
Effectiveness
1
Safety
School of Health Professions, Newark, NJ
Parkinson Disease
Eligibility
18+
All Sexes
Eligible conditions
Parkinson Disease

Study Summary

This study is evaluating whether virtual reality may help Parkinson's disease patients exercise.

See full description

Treatment Effectiveness

Effectiveness Estimate

1 of 3

Compared to trials

Study Objectives

This trial is evaluating whether Treatment will improve 4 primary outcomes, 4 secondary outcomes, and 3 other outcomes in patients with Parkinson Disease. Measurement will happen over the course of Collected once during Day 0 (screening).

Day 1
Cyber sickness Questionnaire
Day 2
Borg Scale for Rate of perceived exertion
Day 2
Enjoyment Ranking
Perceived Effort Ranking
Hour 2
Enjoyment-Motivation
Heart Rate % of maximum
Day 2
Neuromuscular Intensity
Day 2
Physiological Responses to Exercise- Oxygen Consumption
Day 0
Geriatric Depression Scale (short form)
Day 1
Physical Activity Scale for the Elderly
UPDRS-III Subscale

Trial Safety

Safety Estimate

1 of 3

Compared to trials

Trial Design

1 Treatment Groups

Control

This trial requires 60 total participants across 1 different treatment groups

This trial involves a single treatment. Treatment is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.

ControlNo treatment in the control group

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: collected in two sessions: session 1(day 1 for 2 hours) collected continuously during 2 exercise bouts to compare exercise bouts___ session 2 (day 2 for 2 hours) collected continuously in four exercise bouts to compare exercise bouts
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly collected in two sessions: session 1(day 1 for 2 hours) collected continuously during 2 exercise bouts to compare exercise bouts___ session 2 (day 2 for 2 hours) collected continuously in four exercise bouts to compare exercise bouts for reporting.

Who is running the study

Principal Investigator
J. E. D.
Prof. Judith E Deutsch,, PhD
Rutgers, The State University of New Jersey

Closest Location

School of Health Professions - Newark, NJ

Eligibility Criteria

This trial is for patients born any sex aged 18 and older. There are 5 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
Hoehn and Yahr stages II-III
45-75 years old
Diagnosis of Parkinson's disease
able to ride a stationary upright bicycle
able to sign informed consent.

Patient Q&A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Can parkinson disease be cured?

Add answer

There is no evidence that current pharmacological treatments can remove Parkinson's symptoms or prevent their onset. Although there is no cure for PD, most people can improve their quality of life. Moreover, several studies have shown that there is evidence to support PD patients having longer lifespans when they remain well.

Unverified Answer

What causes parkinson disease?

Add answer

The exact cause of Parkinson disease is unknown. Possible triggers from genetics to neuroimaging to physical factors of environmental origin are explored. Smoking, caffeine and alcohol use are all potential causes in the development of Parkinson disease.

Unverified Answer

What are common treatments for parkinson disease?

Add answer

Because no cure for Parkinson's disease exists, most Parkinson's patients begin treatment with the goal of managing symptoms and slowing the progression of the disease. People are encouraged to take exercise. Physical therapy may be helpful in managing rigidity and tremor. Drugs that can help improve motor functioning include levodopa, pramipexole, rotigotine, and ropinirole; however, these may worsen motor symptoms, increase risk for fractures, or reduce the benefits of other Parkinson's treatments. Treatment of hallucinations and dementia by antiparkinson medications (e.g.

Unverified Answer

What is parkinson disease?

Add answer

Symptoms related to PD include stiffness or tremor starting in one hand or foot and worsening over time (though not necessarily simultaneously), resting tremor, slowness of movements, and trouble walking and getting around. PD can occur at any age, often beginning with tremor that worsens over time and involves at least one of tremors, dysarthria (shortness of voice), weakness, and difficulty with handwriting.\n...

Unverified Answer

What are the signs of parkinson disease?

Add answer

Even if many of the symptoms of Parkinson's disease are not noticed at first, medical professionals generally begin to suspect its presence when a patient complains that his or her motor abilities deteriorate over time. If symptoms appear, the diagnosis is usually made when a clinical suspicion exists in a person and a definitive diagnosis can be performed when the course of the disease is studied and supported by an MRI for further examination. To find active clinical trials in your area, you can use [Tynx.

Unverified Answer

How many people get parkinson disease a year in the United States?

Add answer

Approximately 535,000 US adults and children were diagnosed with Parkinson's disease in 1991, the year that the National Institute of Neurological Disorders and Stroke (NINDS) was formed. By 1992, 872,000 people were diagnosed with Parkinson's disease, an increase of more than a decade. The highest rates of disease occurred in men aged 25 to 44 years, women aged 45 to 54, and in rural communities. An estimated 29,700 new cases are diagnosed each year; 70% of these patients are age 45 to 94. At autopsy, a proportion of patients who died a year earlier from this illness in the United States had the abnormal gene that causes Parkinson's disease.

Unverified Answer

What is the primary cause of parkinson disease?

Add answer

The cause of PD is highly variable and complex. Currently, there is no cure for PD. The current therapeutic strategy of medications or surgical procedures may not only relieve symptoms but also delay PD progression but a definite treatment has yet to be proven. In terms of research, a new approach needs to be taken. A larger collaborative multicentre study is needed to understand the pathogenic mechanisms. The identification of specific genes would be useful because PD may lie in genetic malfunction.

Unverified Answer

Is treatment safe for people?

Add answer

There is evidence that the long-term effects of anticholinergics to treat Parkinson's disease may be serious for some people. The risk of long-term effects is increased for people who stop taking the medication and have poor cardiovascular health. Some people are still receiving anticholinergics despite these risks. More information about the long-term effects of anticholinergics is urgently needed in Australia. It is important to have this information available for patients, clinicians, and health systems so they can ensure the optimal use of resources for people with Parkinson's. This article is based on the Australian Parkinson's Disease Foundation, Inc. (APDF). (Australian Guidelines and information Resource).

Unverified Answer

How does treatment work?

Add answer

Treatment of Parkinson's disease with medications has a long history of success and success is still being proven with newer medications still being trialed. It was found that patients with Parkinson’s disease treated with levodopa showed a higher improvement with their condition as treatment increased in time. Levodopa is known to suppress dopamine release in the basal ganglia. Also, the medication may block the activity of dopamine receptors in the subthalamic nucleus of the central nervous system which reduces the dopamine depletion in the striatum and therefore improves the motor symptoms of the disease. In another experiment, it was found that the Parkinson’s disease patients treated with deep brain stimulation also showed a significantly higher improvement than patients not treated with this technology.

Unverified Answer

Who should consider clinical trials for parkinson disease?

Add answer

The current assessment tool for identifying potential clinical trial candidates that may be eligible for a clinical trial is insufficient. This is because the current guideline for identifying candidates for inclusion into a trial requires that potential candidates be eligible for inclusion due to clinical severity. In our sample of PD patients, we found only one candidate, which is not indicative of the proportion of clinically severe PD patients eligible for clinical trial.

Unverified Answer

What are the latest developments in treatment for therapeutic use?

Add answer

Since 2018, medical professionals have been able to use the latest treatments to treat the disease more effectively and help patients live longer. The improvement in the latest treatment could provide a life-saving effect for every patient affected by Parkinson’s Disease. [Power] lets you find out who is most affected by Parkinson’s Disease. [https://power.pro/parkinson-disease/

Unverified Answer

Have there been other clinical trials involving treatment?

Add answer

Given the size of this study, we cannot guarantee the results are generalizable. Further study will be needed to evaluate the effects of bromocriptine on non-parkinsonian degenerative disorders. In addition, we need to compare the results directly in a randomized comparison to dopamine agonists.

Unverified Answer
See if you qualify for this trial
Get access to this novel treatment for Parkinson Disease by sharing your contact details with the study coordinator.